billHR2085•Event Tuesday, March 11, 2025Analyzed

Mental Health Research Accelerator Act of 2025

Bullish

Summary

HR2085 proposes a 25% tax credit for translational research on neurodegenerative and psychiatric conditions, with a $1B aggregate cap in 2026. The bill is in early legislative stage (referred to Ways and Means, zero committee action). The April 18 Executive Order on psychedelic therapies provides a favorable regulatory backdrop but is separate legislation. Pure-play psychedelic/psychiatric biotechs $CMPS, $GHRS, $ATAI are structurally positioned as potential beneficiaries if the bill advances, but the probability of enactment is low at this stage.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

1.HR2085 is an early-stage bill with zero committee action since introduction — do not trade this as a near-term catalyst.
2.The bill's $1B annual cap is small relative to industry-wide R&D; the credit is most impactful for cash-constrained clinical-stage biotechs, but they cannot use credits without net income unless transferability is added.
3.Recent 30-day price surges in $CMPS, $GHRS, and $ATAI are driven by the separate Executive Order on psychedelic therapies, not by this tax legislation.

Market Implications

The market has already priced a favorable regulatory environment for psychedelic therapy developers following the April 18 Executive Order, as reflected in 30-day gains of +51.54% for $CMPS, +38.19% for $GHRS, and +14.97% for $ATAI. However, HR2085 is a separate, early-stage tax bill that offers no near-term catalyst. The 7-day pullbacks suggest the Executive Order rally is consolidating. Until HR2085 advances from committee (unlikely without co-sponsor additions or a Ways and Means markup), investors should treat this as a low-probability tailwind rather than a thesis driver. Pure-play psychiatric biotechs remain structurally tied to regulatory milestones (FDA trial results) and cash runway status, not to early-stage tax credits.

Full Analysis

WHAT HAPPENED: Representative Mike Thompson (D-CA) introduced HR2085, the Mental Health Research Accelerator Act of 2025, on March 11, 2025. The bill was referred to the House Committee on Ways and Means, where it remains without further action. It has 7 cosponsors. The bill proposes adding Section 45BB to the Internal Revenue Code, creating a 25% tax credit for translational research expenses on neurodegenerative diseases (e.g., Alzheimer's, Parkinson's) and psychiatric conditions (e.g., depression, PTSD, anxiety).
MONEY TRAIL: This is a tax credit bill — it does NOT authorize or appropriate federal spending. Instead, it reduces the tax liability of companies that conduct qualifying research. The aggregate national cap is $1B for 2026, rising to $2B annually for 2027-2030, then back to $1B for 2031. Credits are allocated via competitive application by the Treasury Secretary in consultation with HHS, FDA, and NIH. Credits can be carried over if the annual cap is not fully subscribed.
STRUCTURAL WINNERS: Pure-play clinical-stage biotech companies focused on psychiatric conditions — $CMPS, $GHRS, $ATAI — are the most structurally positioned to benefit. These companies have no approved products and thus no taxable income; they cannot utilize tax credits directly unless they can carry them forward or monetize them (e.g., through transferability provisions, which are not specified in the bill). The credit's utility is contingent on future profitability or a transfer market. Large pharmaceutical companies with taxable income (e.g., $PFE, $MRK, $LLY, $JNJ) would be the most capable of using the credit immediately, but the $1B aggregate cap is small relative to their R&D budgets.
RECENT PRICE ACTION: Over the past 30 days, $CMPS has surged +51.54%, $GHRS +38.19%, and $ATAI +14.97%, largely driven by the April 18 Executive Order on psychedelic therapies. The 7-day trends are negative across the board (-12.53%, -4.05%, -12.1%), suggesting a pullback from post-Executive Order highs. $CMPS at $8.38 is near its 52-week high of $10.21; $GHRS at $19.43 is below its $24.66 high; $ATAI at $4.07 is below its $6.75 high. The market has already repriced on regulatory momentum, but the tax credit bill is distinct and early-stage.
TIMELINE: HR2085 requires passage by the House Ways and Means Committee, the full House, the Senate (either identical or via amendment), and either reconciliation or a standalone vote. As an early-stage bill with a partisan sponsor (D-CA) and a fiscal cost (tax credit), its path is long and uncertain. The 119th Congress runs through January 2027; if the bill does not advance to markup this year, it will likely not pass. The April 18 Executive Order does not change the bill's legislative status.

Connected Signals

Matched on shared policy language across AI analyses, with ticker & timing weight

BillStrong LinkBullish

Innovative Therapies Centers of Excellence Act of 2025

Shared: Executive Order · Atai32% match

BillBullish

Freedom to Heal Act of 2025

Shared: Executive Order · April Executive · Atai24% match

BillBullish

Freedom to Heal Act of 2025

Shared: April Executive · Executive Order · Atai19% match

BillNeutral

Veterans Health Administration Novel Therapeutics Preparedness Act

Shared: April Executive · Executive Order · Psychedelic Therapies18% match

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

proclamationNov 3, 2026

THE AMERICAN DECLARATION OF FREEDOM IN SPACE

This proclamation reaffirms U.S. leadership in space exploration, declaring outer space open to development and permanent settlement by American citizens. It sets goals for a return to the Moon by 2028 and a future Mars mission, while emphasizing support for the commercial space industry. The action does not invoke specific legal authorities or direct new funding but signals continued policy focus on space.

5/10Source

proclamationOct 28, 2026

ADJUSTING IMPORTS OF ROBOTICS, INDUSTRIAL MACHINERY, AND THEIR PARTS AND COMPONENTS INTO THE UNITED STATES

The President invokes Section 232 of the Trade Expansion Act to declare that imports of robotics, industrial machinery, and their components threaten national security, and directs the Secretary of Commerce and USTR to negotiate agreements with trading partners to adjust these imports, potentially leading to tariffs or quotas within 180 days.

8/10Source

proclamationOct 22, 2026

Adjusting Imports of Wind Turbines and Their Parts and Components into the United States

This proclamation initiates negotiations to adjust imports of wind turbines and their components under Section 232, citing national security concerns including cybersecurity vulnerabilities, radar interference, and grid reliability. It does not immediately impose tariffs but sets the stage for potential trade restrictions, and notes that certain wind turbine components made of aluminum, steel, or copper are already subject to existing tariffs.

8/10Source

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →